Xenetic Biosciences, INC 8-K filings

Xenetic Biosciences announced its second quarter 2026 financial results, reporting a 12% increase in royalty revenue to $0.7 million, while net loss widened to $0.9 million.

Xenetic Biosciences announced first quarter 2026 financial results, highlighting a 36% increase in royalty revenue and progress in its DNase oncology platform development.

Xenetic Biosciences has awarded 100,000 shares of restricted stock to its Interim CEO and CFO, James Parslow.

Xenetic Biosciences, Inc. announced its full-year 2025 financial results, highlighting progress in its DNase-based immuno-oncology program and a strengthened cash position.

Xenetic Biosciences, Inc. has again adjourned its 2025 Annual Meeting of Stockholders due to a persistent lack of a requisite quorum.

Xenetic Biosciences, Inc. adjourned its 2025 Annual Meeting of Stockholders until January 8, 2026, due to a lack of quorum.

Xenetic Biosciences, Inc. announced its third-quarter 2025 financial results, highlighting increased revenue and a recent capital raise to fund its immuno-oncology programs.

Xenetic Biosciences, Inc. announced the pricing of an underwritten public offering of 735,000 common shares at $6.12 each, aiming to raise approximately $3.9 million in net proceeds.

Xenetic Biosciences announced its second quarter 2025 financial results, highlighting reduced operating expenses and significant progress in its systemic DNase I oncology program through expanded collaborations and patient dosing initiatives.

Xenetic Biosciences announced its Q1 2025 financial results, highlighting a strategic focus on exploratory clinical studies and continued progress in its DNase I development program.

Xenetic Biosciences replaces Marcum LLP with CBIZ CPAs P.C. as its independent registered public accounting firm following Marcum's acquisition by CBIZ.

Xenetic Biosciences announces its full year 2024 financial results, highlighting progress in DNase-based technology for cancer treatment and strategic collaborations.

Xenetic Biosciences announces its full year 2024 financial results, highlighting progress in DNase-based technology for cancer treatment and strategic collaborations.

Xenetic Biosciences, Inc. held its 2024 Annual Meeting of Stockholders, where all six board nominees were elected, Marcum LLP was ratified as the independent auditor, and executive compensation was approved.

Xenetic Biosciences announced its third quarter 2024 financial results, highlighting progress in its DNase-based oncology platform and a focus on strategic partnerships.

Xenetic Biosciences has extended its research agreement with The Scripps Research Institute, providing additional funding to advance its DNase-based oncology platform.

Xenetic Biosciences reports that two board members, James E. Callaway and Adam Logal, will not seek re-election at the upcoming 2024 Annual Meeting of Stockholders.

Xenetic Biosciences announced its second quarter 2024 financial results, reporting a net loss of $1.3 million and providing an update on its DNase-based oncology program.

Xenetic Biosciences has appointed an interim CEO, increased their salary, and finalized separation agreements with the former CEO and CSO.

Xenetic Biosciences has appointed its Chief Financial Officer, James Parslow, as interim CEO, effective May 16, 2024, following the departure of the previous CEO and Chief Scientific Officer.

Xenetic Biosciences announced its first quarter 2024 financial results, highlighting progress in preclinical studies and the advancement of its DNase-based oncology program.

Xenetic Biosciences announced its full year 2023 financial results, highlighting progress in its DNase-based oncology program and a cash balance of $9.0 million.

Xenetic Biosciences released a virtual investor event video featuring their Chief Scientific Officer discussing preclinical data from their DNase I oncology platform.